# FDA Approves Centanafadine for ADHD in Children, Adolescents, and Adults

> **Newsylist Open Intelligence Dossier** · First detected: 2026-07-27 04:29 UTC · Category: Business · Sources: 4 · Current Velocity: 2.5

## Executive Summary
Patients aged six and older now have access to SIMTRIYO, the first new-class ADHD medication approved by the FDA in decades.

## Intelligence Brief
The FDA has granted approval to Otsuka for the use of SIMTRIYO, or centanafadine, to treat attention-deficit hyperactivity disorder in children, adolescents, and adults. As a triple reuptake inhibitor, the drug marks the first medication in a new class for this condition in decades.


FirstWord Pharma notes the significance of the approval for the pharmaceutical market, given the drug's unique mechanism of action. While the agency has confirmed its regulatory green light for patients aged 6 years and older, coverage does not yet specify when the medication will reach commercial pharmacy shelves or the planned distribution timeline for healthcare providers.

## Verified Facts & Key Claims
### What is SIMTRIYO?
SIMTRIYO is a triple reuptake inhibitor known as centanafadine, recently approved by the FDA as a new-class treatment for ADHD.

### Who is eligible to use this medication?
The FDA approved the drug for the treatment of ADHD in children, adolescents, and adults aged 6 years and older.

### Which company produces this drug?
Otsuka is the company that received FDA approval for the medication.

## Key People, Organizations & Locations
FDA Approves Centanafadine for ADHD, Children Adolescents and Adults, Centanafadine's Route, FDA Review A Clinical Path of the ADHD Medication, Otsuka Receives FDA Approval for First-in-Class, Treatment of Attention-Deficit Hyperactivity Disorder ADHD, Adults and Pediatric Patients Aged, Years and Older

## Multi-Source Evidence Table
| Source Outlet | Headline | Published (UTC) | Verification URL |
|---|---|---|---|
| Psychiatric Times | Centanafadine's Route to FDA Review: A Clinical Path of the ADHD Medication | 2026-07-25 05:15 | [Source Link](https://news.google.com/rss/articles/CBMisgFBVV95cUxPWTBDVF9WRzZnVnZqVzNpZi1feVRBZlhHUURadnZEckRkNkVmaGJCdy00TUlvZ1lxS0RCdkxzVEJhZ3V0SVBMQmhLNEVfVzRseHFqV19NQ3dRUkZLVUhBWE1BZGJjQkpXcEx0WUxkMHNBWGhydnlWVHhkcVF6WEx4amhKU1N5WUdSUWNJbTF3NDJCTUlzYjVYdGdWVXJlNVVGS2xDV2xuWnJBci1JZVR0TE5n?oc=5) |
| mykxlg.com | Otsuka Receives FDA Approval for First-in-Class SIMTRIYO® (centanafadine) for the Treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in Adults and Pediatric Patients Aged 6 Years and Older | 2026-07-25 05:15 | [Source Link](https://news.google.com/rss/articles/CBMirgJBVV95cUxNcDFRZFhkM2hlTDJFaDNYQmg0SXM1TDFXLU85VUpsUHFQOFBVS1EyRnBsVGFOaVFDa1VyM0pJdk1VR3JwbDg1US1RMlZNN1U0d3ZrWHYzcndUS21IVVVvdlpJQ0tMTklyUk8wR2F0Y0xuWk1PMkdlM0o4bmQ4blpXVVp2NXZqR01XU19mMXBBcklwdkVXVlpnb3JrSm1CRnJidFBXM05teDI3SVpXcW1WLUxpbFZyWGdmcTBOUFZqZ01Dc2hyVFphbjAtRjZwTDFfalFsa2NldWV5Ql9ZU28zek5XelY3cFJ4TjhIZ1BFQUZHbUtqNFFQeXJDdllMa0V6THZmZ3RJRTJjQ01rcjFWckdSRlR0UHZoSG5WMi1mNlUzZ3luRHN5S1VFSnp6UQ?oc=5) |
| Medical Daily | FDA Rules Today on First New-Class ADHD Drug for Kids and Adults in Decades | 2026-07-25 05:15 | [Source Link](https://news.google.com/rss/articles/CBMijwFBVV95cUxQaGx5ZDNSZGUyeExUcmdmMTM1M0hvQkxrR0wtT3lvRGV1dFRUWXExVFdtdmN3YWR5aXZMRUdBT1hTZThiS21TQVFyY3c3b2ZwUVU0aEk5NG14eHVGN3pwb21qc1ptcXJyeG9JOWJ0enhKbmlxT1FDYlFhUUtiSFIyVkNWaXkxbHFsUjN2djNnTQ?oc=5) |
| FirstWord Pharma | Otsuka's triple reuptake inhibitor Simtriyo wins FDA OK for ADHD | 2026-07-25 05:15 | [Source Link](https://news.google.com/rss/articles/CBMiU0FVX3lxTE1rTTIwMldNUl9jLWpQdzJVcV9xcjN1NWZ2SExRMmR3RkRKdlB6X0RjbWxfbVZjSlNmUmpVUFB5ekFUV2lEa0xJQlFXNzVSd1lOQWdV?oc=5) |
| Psychiatric Times | FDA Approves Centanafadine for ADHD in Children, Adolescents, and Adults | 2026-07-25 05:15 | [Source Link](https://news.google.com/rss/articles/CBMirAFBVV95cUxNWVpXRXJiNWVVbkt2TlhESndrV1FQUi1abjJqejNxb0pDR2ZWVDNWZElZN1hUb2dCZlU5WkFMSGF0Q1ZLZURGdjhpQzc1cEQ3d2tRa0EzbzcxRl9keWxhb1E4cGl5eFVRY2V5VXI3Z3FzQm9OdTJrSUdzRE5hUUlOSl80WXdIRVMteGtnalB5OUFDVGxLSFpXQkxQajhhV3VvRGk0LXBlNTNHdllT?oc=5) |

---
*Canonical Source: https://www.newsylist.com/trend/2026-07-27/fda-approves-centanafadine-for-adhd-in-children-adolescents-and-adults*
*Synthesized by Newsylist Open Intelligence Engine under E-E-A-T journalistic standards.*